TrialThe Journal of clinical investigation1993

V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.

D C Montefiori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.